8/13/2004

Scotland's Shire Pharmaceuticals announced it has received approval from the FDA for the sale of its Adderall XR attention deficit hyperactivity disorder treatment for adults in the U.S. The company already has approval to market the drug for treatment of children and says it will begin marketing to adults immediately. Adderall XR is the most-prescribed brand for ADHD treatment in the states, and Shire says sales to adults could be double that for children.

Related Summaries